Arvelle Therapeutics

Acquired by Angelini Pharma
Developed Ontozry™ (cenobamate) to treat epilepsy.
Developed Ontozry™ (cenobamate) to treat epilepsy.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Basel, Switzerland

Initial Investment

2019
Arvelle Therapeutics

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.  Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.